{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:42:24Z","timestamp":1789688544663,"version":"4.0.1"},"reference-count":134,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-025-11367-5","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T13:34:47Z","timestamp":1766064887000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Gatekeepers of immunity: mechanisms and regulation of immune checkpoints and their role in immune-privileged sites"],"prefix":"10.1007","volume":"53","author":[{"given":"Reza Nejad Shahrokh","family":"Abadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra Nejad Shahrokh","family":"Abadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Hooshmand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"issue":"3","key":"11367_CR1","first-page":"727","volume":"10","author":"Y Han","year":"2020","unstructured":"Han Y, Liu D, Li L (2020) PD-1\/PD-L1 pathway: current researches in cancer. Am J Cancer Res 10(3):727\u2013742","journal-title":"Am J Cancer Res"},{"issue":"8","key":"11367_CR2","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","volume":"30","author":"X He","year":"2020","unstructured":"He X, Xu C (2020) Immune checkpoint signaling and cancer immunotherapy. Cell Res 30(8):660\u2013669","journal-title":"Cell Res"},{"issue":"1","key":"11367_CR3","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000239","volume":"39","author":"EI Buchbinder","year":"2016","unstructured":"Buchbinder EI, Desai A (2016) CTLA-4 and PD-1 pathways: Similarities, Differences, and implications of their Inhibition. Am J Clin Oncol 39(1):98\u2013106","journal-title":"Am J Clin Oncol"},{"key":"11367_CR4","doi-asserted-by":"publisher","unstructured":"Garcia-Perez JE, Baxter RM, Kong DS, Tobin R, McCarter M, Routes JM et al (2019) CTLA4 Message Reflects Pathway Disruption in Monogenic Disorders and Under Therapeutic Blockade [Internet]. Vol. 10, Frontiers in Immunology. Available from: https:\/\/www.frontiersin.org\/articles\/https:\/\/doi.org\/10.3389\/fimmu.2019.00998","DOI":"10.3389\/fimmu.2019.00998"},{"issue":"1","key":"11367_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1091-2","volume":"18","author":"S Qin","year":"2019","unstructured":"Qin S, Xu L, Yi M, Yu S, Wu K, Luo S (2019) Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer 18(1):155. https:\/\/doi.org\/10.1186\/s12943-019-1091-2","journal-title":"Mol Cancer"},{"issue":"1","key":"11367_CR6","doi-asserted-by":"publisher","DOI":"10.1093\/immadv\/ltab025","volume":"2","author":"SEA Burnell","year":"2022","unstructured":"Burnell SEA, Capitani L, MacLachlan BJ, Mason GH, Gallimore AM, Godkin A (2022) Seven mysteries of LAG-3: a multi-faceted immune receptor of increasing complexity. Immunother Adv 2(1):ltab025. https:\/\/doi.org\/10.1093\/immadv\/ltab025","journal-title":"Immunother Adv"},{"key":"11367_CR7","doi-asserted-by":"crossref","unstructured":"Maruhashi T, Sugiura D, Okazaki I, Okazaki T (2020) LAG-3: from molecular functions to clinical applications. J Immunother Cancer [Internet];8(2):e001014. Available from: http:\/\/jitc.bmj.com\/content\/8\/2\/e001014.abstract","DOI":"10.1136\/jitc-2020-001014"},{"key":"11367_CR8","doi-asserted-by":"publisher","unstructured":"Tian T, Li Z (2021) Targeting Tim-3 in Cancer With Resistance to PD-1\/PD-L1 Blockade [Internet]. Vol. 11, Frontiers in Oncology. Available from: https:\/\/www.frontiersin.org\/articles\/https:\/\/doi.org\/10.3389\/fonc.2021.731175","DOI":"10.3389\/fonc.2021.731175"},{"key":"11367_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000911","author":"N Acharya","year":"2020","unstructured":"Acharya N, Sabatos-Peyton C, Anderson AC (2020) Tim-3 finds its place in the cancer immunotherapy landscape (2020) J Immunother Cancer 8(1):e000911. https:\/\/doi.org\/10.1136\/jitc-2020-000911","journal-title":"J Immunother Cancer"},{"key":"11367_CR10","doi-asserted-by":"publisher","first-page":"7005","DOI":"10.2147\/OTT.S170385","volume":"11","author":"Y He","year":"2018","unstructured":"He Y, Cao J, Zhao C, Li X, Zhou C, Hirsch FR (2018) TIM-3, a promising target for cancer immunotherapy. Onco Targets Ther 11:7005\u20137009","journal-title":"Onco Targets Ther"},{"key":"11367_CR11","doi-asserted-by":"publisher","first-page":"731798","DOI":"10.3389\/fphar.2021.731798","volume":"12","author":"J Liu","year":"2021","unstructured":"Liu J, Chen Z, Li Y, Zhao W, Wu J, Zhang Z (2021) PD-1\/PD-L1 checkpoint inhibitors in tumor immunotherapy. Front Pharmacol 12:731798","journal-title":"Front Pharmacol"},{"key":"11367_CR12","doi-asserted-by":"publisher","unstructured":"Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK et al (2017) PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome [Internet]. Vol. 8, Frontiers in Pharmacology. Available from: https:\/\/www.frontiersin.org\/articles\/https:\/\/doi.org\/10.3389\/fphar.2017.00561","DOI":"10.3389\/fphar.2017.00561"},{"key":"11367_CR13","doi-asserted-by":"crossref","unstructured":"Pauken KE, Torchia JA, Chaudhri A, Sharpe AH, Freeman GJ (2021) Emerging concepts in PD-1 checkpoint biology. Semin Immunol [Internet];52:101480. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1044532321000117","DOI":"10.1016\/j.smim.2021.101480"},{"key":"11367_CR14","doi-asserted-by":"crossref","unstructured":"Rowshanravan B, Halliday N, Sansom DM (2018) CTLA-4: a moving target in immunotherapy. Blood [Internet];131(1):58\u201367. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0006497120325854","DOI":"10.1182\/blood-2017-06-741033"},{"issue":"1","key":"11367_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-021-01987-7","volume":"40","author":"H Zhang","year":"2021","unstructured":"Zhang H, Dai Z, Wu W, Wang Z, Zhang N, Zhang L et al (2021) Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. J Exp Clin Cancer Res 40(1):184. https:\/\/doi.org\/10.1186\/s13046-021-01987-7","journal-title":"J Exp Clin Cancer Res"},{"key":"11367_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19103044","author":"S Terry","year":"2018","unstructured":"Terry S, Faouzi Zaarour R, Hassan Venkatesh G, Francis A, El-Sayed W, Buart S, Bravo P, Thiery J, Chouaib S (2018) Role of Hypoxic Stress in Regulating Tumor Immunogenicity, Resistance and Plasticity. Int J Mol Sci 6;19(10):3044. https:\/\/doi.org\/10.3390\/ijms19103044","journal-title":"Int J Mol Sci"},{"key":"11367_CR17","doi-asserted-by":"crossref","unstructured":"Chiang EY, Mellman I (2022) TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy. J Immunother Cancer [Internet];10(4):e004711. Available from: http:\/\/jitc.bmj.com\/content\/10\/4\/e004711.abstract","DOI":"10.1136\/jitc-2022-004711"},{"key":"11367_CR18","doi-asserted-by":"crossref","unstructured":"Chauvin J-M, Zarour HM (2020) TIGIT in cancer immunotherapy. J Immunother Cancer [Internet];8(2):e000957. Available from: http:\/\/jitc.bmj.com\/content\/8\/2\/e000957.abstract","DOI":"10.1136\/jitc-2020-000957"},{"key":"11367_CR19","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.3389\/fimmu.2018.02306","volume":"9","author":"C Paluch","year":"2018","unstructured":"Paluch C, Santos AM, Anzilotti C, Cornall RJ, Davis SJ (2018) Immune checkpoints as therapeutic targets in autoimmunity. Front Immunol 9:2306","journal-title":"Front Immunol"},{"key":"11367_CR20","doi-asserted-by":"publisher","DOI":"10.1172\/JCI159473","author":"MR Shurin","year":"2022","unstructured":"Shurin MR, Umansky V (2022) Cross-talk between HIF and PD-1\/PD-L1 pathways in carcinogenesis and therapy. J Clin Invest 132(9):e159473. https:\/\/doi.org\/10.1172\/JCI159473","journal-title":"J Clin Invest"},{"issue":"12","key":"11367_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18122540","volume":"18","author":"Q Wang","year":"2017","unstructured":"Wang Q, Lin W, Tang X, Li S, Guo L, Lin Y et al (2017) The roles of microRNAs in regulating the expression of PD-1\/PD-L1 immune checkpoint. Int J Mol Sci 18(12):2540","journal-title":"Int J Mol Sci"},{"issue":"33","key":"11367_CR22","doi-asserted-by":"publisher","first-page":"53735","DOI":"10.18632\/oncotarget.10731","volume":"7","author":"Q Li","year":"2016","unstructured":"Li Q, Johnston N, Zheng X, Wang H, Zhang X, Gao D et al (2016) MiR-28 modulates exhaustive differentiation of T cells through silencing programmed cell death-1 and regulating cytokine secretion. Oncotarget 7(33):53735\u201353750","journal-title":"Oncotarget"},{"issue":"1","key":"11367_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-017-0474-y","volume":"17","author":"L Boldrini","year":"2017","unstructured":"Boldrini L, Giordano M, Niccoli C, Melfi F, Lucchi M, Mussi A et al (2017) Role of microRNA-33a in regulating the expression of PD-1 in lung adenocarcinoma. Cancer Cell Int 17(1):105. https:\/\/doi.org\/10.1186\/s12935-017-0474-y","journal-title":"Cancer Cell Int"},{"issue":"Suppl 1","key":"11367_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/2051-1426-1-S1-P177","volume":"1","author":"J Wei","year":"2013","unstructured":"Wei J, Nduom E, Kong L-Y, Wang F, Xu S, Gabrusiewicz K et al (2013) miR-138 exerts anti-glioma efficacy by targeting immune checkpoints. J Immunother Cancer 1(Suppl 1):P177. https:\/\/doi.org\/10.1186\/2051-1426-1-S1-P177","journal-title":"J Immunother Cancer"},{"key":"11367_CR25","doi-asserted-by":"publisher","first-page":"144888","DOI":"10.1016\/j.gene.2020.144888","volume":"754","author":"N Skafi","year":"2020","unstructured":"Skafi N, Fayyad-Kazan M, Badran B (2020) Immunomodulatory role for micrornas: regulation of PD-1\/PD-L1 and CTLA-4 immune checkpoints expression. Gene 754:144888","journal-title":"Gene"},{"issue":"4","key":"11367_CR26","first-page":"4797","volume":"15","author":"F Huang","year":"2018","unstructured":"Huang F, Wang B, Zeng J, Sang S, Lei J, Lu Y (2018) Microrna-374b inhibits liver cancer progression via down regulating programmed cell death-1 expression on cytokine-induced killer cells. Oncol Lett 15(4):4797\u20134804","journal-title":"Oncol Lett"},{"issue":"22","key":"11367_CR27","doi-asserted-by":"publisher","first-page":"18933","DOI":"10.18632\/oncotarget.3662","volume":"6","author":"G Zhang","year":"2015","unstructured":"Zhang G, Li N, Li Z, Zhu Q, Li F, Yang C et al (2015) Microrna-4717 differentially interacts with its polymorphic target in the PD1 3\u2019 untranslated region: a mechanism for regulating PD-1 expression and function in HBV-associated liver diseases. Oncotarget 6(22):18933\u201344","journal-title":"Oncotarget"},{"issue":"6","key":"11367_CR28","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1002\/2211-5463.12853","volume":"10","author":"J Huang","year":"2020","unstructured":"Huang J, Weng Q, Shi Y, Mao W, Zhao Z, Wu R et al (2020) MicroRNA-155-5p suppresses PD-L1 expression in lung adenocarcinoma. FEBS Open Bio 10(6):1065\u20131071","journal-title":"FEBS Open Bio"},{"issue":"1","key":"11367_CR29","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12943-019-0977-3","volume":"18","author":"Z Zheng","year":"2019","unstructured":"Zheng Z, Sun R, Zhao H-J, Fu D, Zhong H-J, Weng X-Q et al (2019) Mir155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1\/PD-L1-mediated lymphoma cell interaction with CD8\u2009+\u2009T cells. Mol Cancer 18(1):54","journal-title":"Mol Cancer"},{"issue":"23","key":"11367_CR30","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1038\/s41388-018-0178-3","volume":"37","author":"J Xi","year":"2018","unstructured":"Xi J, Huang Q, Wang L, Ma X, Deng Q, Kumar M et al (2018) MiR-21 depletion in macrophages promotes tumoricidal polarization and enhances PD-1 immunotherapy. Oncogene 37(23):3151\u201365. https:\/\/doi.org\/10.1038\/s41388-018-0178-3","journal-title":"Oncogene"},{"issue":"39","key":"11367_CR31","doi-asserted-by":"publisher","first-page":"5257","DOI":"10.1038\/s41388-018-0347-4","volume":"37","author":"P Dong","year":"2018","unstructured":"Dong P, Xiong Y, Yu J, Chen L, Tao T, Yi S et al (2018) Control of PD-L1 expression by miR-140\/142\/340\/383 and oncogenic activation of the OCT4\u2013miR-18a pathway in cervical cancer. Oncogene 37(39):5257\u201368. https:\/\/doi.org\/10.1038\/s41388-018-0347-4","journal-title":"Oncogene"},{"issue":"6","key":"11367_CR32","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1158\/1541-7786.MCR-18-0831","volume":"17","author":"M Ashizawa","year":"2019","unstructured":"Ashizawa M, Okayama H, Ishigame T, Thar Min AK, Saito K, Ujiie D et al (2019) miRNA-148a-3p regulates immunosuppression in DNA mismatch Repair-Deficient colorectal cancer by targeting PD-L1. Mol Cancer Res 17(6):1403\u20131413","journal-title":"Mol Cancer Res"},{"key":"11367_CR33","doi-asserted-by":"publisher","first-page":"5241","DOI":"10.1038\/ncomms6241","volume":"5","author":"L Chen","year":"2014","unstructured":"Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn Y-H, Byers LA et al (2014) Metastasis is regulated via microRNA-200\/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun 5:5241","journal-title":"Nat Commun"},{"issue":"3","key":"11367_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0090022","volume":"9","author":"Y Shi","year":"2014","unstructured":"Shi Y, Liu C, Liu X, Tang DG, Wang J (2014) The microrna miR-34a inhibits non-small cell lung cancer (NSCLC) growth and the CD44hi stem-like NSCLC cells. PLoS One 9(3):e90022. https:\/\/doi.org\/10.1371\/journal.pone.0090022","journal-title":"PLoS One"},{"issue":"1","key":"11367_CR35","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1158\/0008-5472.CAN-18-1397","volume":"79","author":"J Mastroianni","year":"2019","unstructured":"Mastroianni J, Stickel N, Andrlova H, Hanke K, Melchinger W, Duquesne S et al (2019) Mir-146a controls immune response in the melanoma microenvironment. Cancer Res 79(1):183\u201395","journal-title":"Cancer Res"},{"key":"11367_CR36","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.ebiom.2019.02.034","volume":"41","author":"L Gao","year":"2019","unstructured":"Gao L, Guo Q, Li X, Yang X, Ni H, Wang T et al (2019) Mir-873\/PD-L1 axis regulates the stemness of breast cancer cells. EBioMedicine 41:395\u2013407","journal-title":"EBioMedicine"},{"issue":"9","key":"11367_CR37","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.jtho.2017.05.024","volume":"12","author":"SC Kao","year":"2017","unstructured":"Kao SC, Cheng YY, Williams M, Kirschner MB, Madore J, Lum T et al (2017) Tumor suppressor micrornas contribute to the regulation of PD-L1 expression in malignant pleural\u00a0mesothelioma. J Thorac Oncol 12(9):1421\u201333. https:\/\/doi.org\/10.1016\/j.jtho.2017.05.024","journal-title":"J Thorac Oncol"},{"issue":"13","key":"11367_CR38","doi-asserted-by":"publisher","first-page":"21609","DOI":"10.18632\/oncotarget.15450","volume":"8","author":"M Cioffi","year":"2017","unstructured":"Cioffi M, Trabulo SM, Vallespinos M, Raj D, Kheir TB, Lin M-L et al (2017) The miR-25-93-106b cluster regulates tumor metastasis and immune evasion via modulation of CXCL12 and PD-L1. Oncotarget 8(13):21609\u201321625","journal-title":"Oncotarget"},{"issue":"29","key":"11367_CR39","doi-asserted-by":"publisher","first-page":"45370","DOI":"10.18632\/oncotarget.9659","volume":"7","author":"L Zhao","year":"2016","unstructured":"Zhao L, Yu H, Yi S, Peng X, Su P, Xiao Z et al (2016) The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer. Oncotarget 7(29):45370\u201345384","journal-title":"Oncotarget"},{"key":"11367_CR40","doi-asserted-by":"crossref","unstructured":"Jia L, Xi Q, Wang H, Zhang Z, Liu H, Cheng Y et al (2017) miR-142-5p regulates tumor cell PD-L1 expression and enhances anti-tumor immunity. Biochem Biophys Res Commun [Internet];488(2):425\u2013431. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0006291X17309488","DOI":"10.1016\/j.bbrc.2017.05.074"},{"issue":"17","key":"11367_CR41","doi-asserted-by":"publisher","first-page":"28125","DOI":"10.18632\/oncotarget.15924","volume":"8","author":"Y Wang","year":"2017","unstructured":"Wang Y, Wang D, Xie G, Yin Y, Zhao E, Tao K et al (2017) Microrna-152 regulates immune response via targeting B7-H1 in gastric carcinoma. Oncotarget 8(17):28125\u201328134","journal-title":"Oncotarget"},{"issue":"1","key":"11367_CR42","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s12943-024-02201-w","volume":"23","author":"H Luo","year":"2024","unstructured":"Luo H, Hu B, Gu X-R, Chen J, Fan X-Q, Zhang W et al (2024) The miR-23a\/27a\/24\u2009\u2013\u20092 cluster drives immune evasion and resistance to PD-1\/PD-L1 blockade in non-small cell lung cancer. Mol Cancer 23(1):285","journal-title":"Mol Cancer"},{"issue":"3","key":"11367_CR43","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1159\/000494544","volume":"50","author":"F He","year":"2018","unstructured":"He F, Zhou Y, Wang X, Li L, Geng Y, Wang Z et al (2018) Functional polymorphisms of CTLA4 associated with aggressive periodontitis in the Chinese Han population. Cell Physiol Biochem 50(3):1178\u201385. https:\/\/doi.org\/10.1159\/000494544","journal-title":"Cell Physiol Biochem"},{"key":"11367_CR44","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.diabres.2018.05.044","volume":"142","author":"M Zurawek","year":"2018","unstructured":"Zurawek M, Dzikiewicz-Krawczyk A, Izykowska K, Ziolkowska-Suchanek I, Skowronska B, Czainska M et al (2018) Mir-487a-3p upregulated in type 1 diabetes targets CTLA4 and FOXO3. Diabetes Res Clin Pract 142:146\u201353","journal-title":"Diabetes Res Clin Pract"},{"key":"11367_CR45","doi-asserted-by":"publisher","unstructured":"Kunze-Schumacher H, Krueger A (2020) The Role of MicroRNAs in Development and Function of Regulatory T Cells \u2013 Lessons for a Better Understanding of MicroRNA Biology [Internet]. Vol. 11, Frontiers in Immunology. Available from: https:\/\/www.frontiersin.org\/articles\/https:\/\/doi.org\/10.3389\/fimmu.2020.02185","DOI":"10.3389\/fimmu.2020.02185"},{"issue":"3","key":"11367_CR46","doi-asserted-by":"publisher","first-page":"e2006716","DOI":"10.1371\/journal.pbio.2006716","volume":"17","author":"M \u0141yszkiewicz","year":"2019","unstructured":"\u0141yszkiewicz M, Winter SJ, Witzlau K, F\u00f6hse L, Brownlie R, Pucha\u0142ka J et al (2019) Mir-181a\/b-1 controls thymic selection of Treg cells and tunes their suppressive capacity. PLoS Biol 17(3):e2006716","journal-title":"PLoS Biol"},{"issue":"9","key":"11367_CR47","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1111\/ajt.12834","volume":"14","author":"D Gardner","year":"2014","unstructured":"Gardner D, Jeffery LE, Sansom DM (2014) Understanding the CD28\/CTLA-4 (CD152) pathway and its implications for costimulatory blockade. Am J Transplant 14(9):1985\u201391. https:\/\/doi.org\/10.1111\/ajt.12834","journal-title":"Am J Transplant"},{"issue":"1","key":"11367_CR48","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/imm.13343","volume":"164","author":"D Janman","year":"2021","unstructured":"Janman D, Hinze C, Kennedy A, Halliday N, Waters E, Williams C et al (2021) Regulation of CTLA-4 recycling by LRBA and Rab11. Immunology 164(1):106\u201319","journal-title":"Immunology"},{"key":"11367_CR49","doi-asserted-by":"publisher","unstructured":"Huo J-L, Wang Y-T, Fu W-J, Lu N, Liu Z-S (2022) The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application [Internet]. Vol. 13, Frontiers in Immunology. Available from: https:\/\/www.frontiersin.org\/articles\/https:\/\/doi.org\/10.3389\/fimmu.2022.956090","DOI":"10.3389\/fimmu.2022.956090"},{"key":"11367_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22105282","author":"L Chocarro","year":"2021","unstructured":"Chocarro L, Blanco E, Zuazo M, Arasanz H, Bocanegra A, Fern\u00e1ndez-Rubio L, Morente P, Fern\u00e1ndez-Hinojal G, Echaide M, Garnica M, Ramos P, Vera R, Kochan G, Escors D (2021) Understanding LAG-3 Signaling. Int J Mol Sci 22(10):5282. https:\/\/doi.org\/10.3390\/ijms22105282","journal-title":"Int J Mol Sci"},{"key":"11367_CR51","doi-asserted-by":"crossref","unstructured":"Previte DM, Martins CP, O\u2019Connor EC, Marre ML, Coudriet GM, Beck NW et al (2019) Lymphocyte Activation Gene-3 Maintains Mitochondrial and Metabolic Quiescence in Naive CD4\u2009+\u2009T Cells. Cell Rep [Internet]. ;27(1):129\u2013141.e4. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2211124719303110","DOI":"10.1016\/j.celrep.2019.03.004"},{"key":"11367_CR52","doi-asserted-by":"publisher","unstructured":"Zhu C, Dixon KO, Newcomer K, Gu G, Xiao S, Zaghouani S et al (2022) Tim-3 adaptor protein Bat3 is a molecular checkpoint of T cell terminal differentiation and exhaustion. Sci Adv [Internet]. ;7(18):eabd2710. Available from: https:\/\/doi.org\/10.1126\/sciadv.abd2710","DOI":"10.1126\/sciadv.abd2710"},{"issue":"3","key":"11367_CR53","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","volume":"20","author":"Y Wolf","year":"2020","unstructured":"Wolf Y, Anderson AC, Kuchroo VK (2020) TIM3 comes of age as an inhibitory receptor. Nat Rev Immunol 20(3):173\u201385. https:\/\/doi.org\/10.1038\/s41577-019-0224-6","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"11367_CR54","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/S0161-5890(01)00108-0","volume":"38","author":"G Ermak","year":"2002","unstructured":"Ermak G, Davies KJA (2002) Calcium and oxidative stress: from cell signaling to cell death. Mol Immunol 38(10):713\u2013721","journal-title":"Mol Immunol"},{"key":"11367_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.871085","volume":"12","author":"T Annese","year":"2022","unstructured":"Annese T, Tamma R, Ribatti D (2022) Update in TIGIT Immune-Checkpoint Role in Cancer. Front Oncol 12:871085","journal-title":"Front Oncol"},{"issue":"2","key":"11367_CR56","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/cei.13407","volume":"200","author":"H Harjunp\u00e4\u00e4","year":"2020","unstructured":"Harjunp\u00e4\u00e4 H, Guillerey C (2020) Tigit as an emerging immune checkpoint. Clin Exp Immunol 200(2):108\u2013119","journal-title":"Clin Exp Immunol"},{"key":"11367_CR57","doi-asserted-by":"publisher","unstructured":"Ge Z, Peppelenbosch MP, Sprengers D, Kwekkeboom J (2021) TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer [Internet]. Vol. 12, Frontiers in Immunology. Available from: https:\/\/www.frontiersin.org\/articles\/https:\/\/doi.org\/10.3389\/fimmu.2021.699895","DOI":"10.3389\/fimmu.2021.699895"},{"key":"11367_CR58","doi-asserted-by":"publisher","unstructured":"Ning Z, Liu K, Xiong H (2021) Roles of BTLA in Immunity and Immune Disorders [Internet]. Vol. 12, Frontiers in Immunology. Available from: https:\/\/www.frontiersin.org\/articles\/https:\/\/doi.org\/10.3389\/fimmu.2021.654960","DOI":"10.3389\/fimmu.2021.654960"},{"issue":"1","key":"11367_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0744-4","volume":"7","author":"Y-L Chen","year":"2019","unstructured":"Chen Y-L, Lin H-W, Chien C-L, Lai Y-L, Sun W-Z, Chen C-A et al (2019) BTLA blockade enhances cancer therapy by inhibiting IL-6\/IL-10-induced CD19high B lymphocytes. J Immunother Cancer 7(1):313. https:\/\/doi.org\/10.1186\/s40425-019-0744-4","journal-title":"J Immunother Cancer"},{"issue":"12","key":"11367_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110553","volume":"38","author":"C Stienne","year":"2022","unstructured":"Stienne C, Virgen-Slane R, Elm\u00e9n L, Veny M, Huang S, Nguyen J et al (2022) Btla signaling in conventional and regulatory lymphocytes coordinately tempers humoral immunity in the intestinal mucosa. Cell Rep 38(12):110553","journal-title":"Cell Rep"},{"key":"11367_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21113962","author":"J Hori","year":"2020","unstructured":"Hori J, Kunishige T, Nakano Y (2020) Immune checkpoints contribute corneal immune privilege: implications for dry eye associated with checkpoint inhibitors. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms21113962","journal-title":"Int J Mol Sci"},{"key":"11367_CR62","doi-asserted-by":"crossref","unstructured":"Zhou R, Caspi RR (2010) Ocular immune privilege. F1000. Biol Rep. ;2","DOI":"10.3410\/B2-3"},{"key":"11367_CR63","doi-asserted-by":"publisher","unstructured":"Taylor AW (2016) Ocular Immune Privilege and Transplantation [Internet]. Vol. 7, Frontiers in Immunology. Available from: https:\/\/www.frontiersin.org\/articles\/https:\/\/doi.org\/10.3389\/fimmu.2016.00037","DOI":"10.3389\/fimmu.2016.00037"},{"issue":"2","key":"11367_CR64","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3109\/09273941003669950","volume":"18","author":"KC McKenna","year":"2010","unstructured":"McKenna KC, Chen PW (2010) Influence of immune privilege on ocular tumor development. Ocul Immunol Inflamm 18(2):80\u201390","journal-title":"Ocul Immunol Inflamm"},{"key":"11367_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2020.102441","volume":"111","author":"F Muhammad","year":"2020","unstructured":"Muhammad F, Wang D, McDonald T, Walsh M, Drenen K, Montieth A et al (2020) TIGIT(+) A2Ar-Dependent anti-uveitic Treg cells are a novel subset of Tregs associated with resolution of autoimmune uveitis. J Autoimmun 111:102441","journal-title":"J Autoimmun"},{"issue":"1","key":"11367_CR66","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/j.1600-065X.2006.00433.x","volume":"213","author":"P Mrass","year":"2006","unstructured":"Mrass P, Weninger W (2006) Immune cell migration as a means to control immune privilege: lessons from the CNS and tumors. Immunol Rev 213(1):195\u2013212. https:\/\/doi.org\/10.1111\/j.1600-065X.2006.00433.x","journal-title":"Immunol Rev"},{"issue":"6","key":"11367_CR67","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1093\/jnen\/62.6.593","volume":"1","author":"JS Pachter","year":"2003","unstructured":"Pachter JS, de Vries HE, Fabry Z (2003) The blood-brain barrier and its role in immune privilege in the central nervous system. J Neuropathol Exp Neurol 1(6):593\u2013604. https:\/\/doi.org\/10.1093\/jnen\/62.6.593","journal-title":"J Neuropathol Exp Neurol"},{"issue":"11","key":"11367_CR68","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41583-018-0070-8","volume":"19","author":"JV Forrester","year":"2018","unstructured":"Forrester JV, McMenamin PG, Dando SJ (2018) CNS infection and immune privilege. Nat Rev Neurosci 19(11):655\u201371. https:\/\/doi.org\/10.1038\/s41583-018-0070-8","journal-title":"Nat Rev Neurosci"},{"key":"11367_CR69","doi-asserted-by":"crossref","unstructured":"Louveau A, Harris TH, Kipnis J (2015) Revisiting the Mechanisms of CNS Immune Privilege. Trends Immunol [Internet];36(10):569\u2013577. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1471490615001982","DOI":"10.1016\/j.it.2015.08.006"},{"issue":"6","key":"11367_CR70","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/s41593-018-0145-x","volume":"21","author":"A Deczkowska","year":"2018","unstructured":"Deczkowska A, Amit I, Schwartz M (2018) Microglial immune checkpoint mechanisms. Nat Neurosci 21(6):779\u201386. https:\/\/doi.org\/10.1038\/s41593-018-0145-x","journal-title":"Nat Neurosci"},{"issue":"2","key":"11367_CR71","doi-asserted-by":"publisher","DOI":"10.1111\/aji.12710","volume":"1","author":"L-L Wang","year":"2017","unstructured":"Wang L-L, Li Z-H, Hu X-H, Muyayalo KP, Zhang Y-H, Liao A-H (2017) The roles of the PD-1\/PD-L1 pathway at immunologically privileged sites. Am J Reprod Immunol 1(2):e12710. https:\/\/doi.org\/10.1111\/aji.12710","journal-title":"Am J Reprod Immunol"},{"key":"11367_CR72","doi-asserted-by":"publisher","unstructured":"Gimsa U, \u00d8ren A, Pandiyan P, Teichmann D, Bechmann I, Nitsch R et al (2004) Astrocytes protect the CNS: antigen-specific T helper cell responses are inhibited by astrocyte-induced upregulation of CTLA-4 (CD152). J Mol Med [Internet];82(6):364\u2013372. Available from: https:\/\/doi.org\/10.1007\/s00109-004-0531-6","DOI":"10.1007\/s00109-004-0531-6"},{"key":"11367_CR73","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000712","author":"LE Lucca","year":"2020","unstructured":"Lucca LE, Lerner BA, Park C, DeBartolo D, Harnett B, Kumar VP et al (2020) Differential expression of the T-cell inhibitor TIGIT in glioblastoma and MS. Neurology Neuroimmunology & Neuroinflammation. https:\/\/doi.org\/10.1212\/NXI.0000000000000712","journal-title":"Neurology Neuroimmunology & Neuroinflammation"},{"issue":"3","key":"11367_CR74","doi-asserted-by":"publisher","DOI":"10.1111\/aji.13212","volume":"1","author":"M Meggyes","year":"2020","unstructured":"Meggyes M, Lajko A, Fulop BD, Reglodi D, Szereday L (2020) Phenotypic characterization of testicular immune cells expressing immune checkpoint molecules in wild-type and pituitary adenylate cyclase-activating polypeptide-deficient mice. Am J Reprod Immunol 1(3):e13212. https:\/\/doi.org\/10.1111\/aji.13212","journal-title":"Am J Reprod Immunol"},{"key":"11367_CR75","doi-asserted-by":"publisher","unstructured":"Li N, Wang T, Han D (2012) Structural, cellular and molecular aspects of immune privilege in the testis [Internet]. Vol. 3, Frontiers in Immunology. Available from: https:\/\/www.frontiersin.org\/articles\/https:\/\/doi.org\/10.3389\/fimmu.2012.00152","DOI":"10.3389\/fimmu.2012.00152"},{"key":"11367_CR76","doi-asserted-by":"crossref","unstructured":"McColl ER, Vassileva V, Piquette-Miller M (2022) 1.23 - Drug Transporters: Efflux. In: Kenakin TBT-CP (ed) Oxford: Elsevier; pp 608\u2013626. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/B9780128204726000542","DOI":"10.1016\/B978-0-12-820472-6.00054-2"},{"key":"11367_CR77","doi-asserted-by":"crossref","unstructured":"de Kretser DM, Loveland K, O\u2019Bryan M (2016) Chapter 136 - Spermatogenesis. In: Jameson JL, De Groot LJ, de Kretser DM, Giudice LC, Grossman AB, Melmed S, editors. Philadelphia: W.B. Saunders; pp. 2325\u20132353.e9. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/B9780323189071001360","DOI":"10.1016\/B978-0-323-18907-1.00136-0"},{"issue":"5","key":"11367_CR78","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/cmi.2014.38","volume":"11","author":"S Zhao","year":"2014","unstructured":"Zhao S, Zhu W, Xue S, Han D (2014) Testicular defense systems: immune privilege and innate immunity. Cell Mol Immunol 11(5):428\u201337. https:\/\/doi.org\/10.1038\/cmi.2014.38","journal-title":"Cell Mol Immunol"},{"key":"11367_CR79","doi-asserted-by":"crossref","unstructured":"Morianos I, Papadopoulou G, Semitekolou M, Xanthou G (2019) Activin-A in the regulation of immunity in health and disease. J Autoimmun [Internet];104:102314. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0896841119304743","DOI":"10.1016\/j.jaut.2019.102314"},{"key":"11367_CR80","doi-asserted-by":"publisher","unstructured":"Jasinski-Bergner S, Eckstein M, Taubert H, Wach S, Fiebig C, Strick R et al (2022) The Human Leukocyte Antigen G as an Immune Escape Mechanism and Novel Therapeutic Target in Urological Tumors [Internet]. Vol. 13, Frontiers in Immunology. Available from: https:\/\/www.frontiersin.org\/articles\/https:\/\/doi.org\/10.3389\/fimmu.2022.811200","DOI":"10.3389\/fimmu.2022.811200"},{"key":"11367_CR81","doi-asserted-by":"crossref","unstructured":"Meinhardt A, Hedger MP (2011) Immunological, paracrine and endocrine aspects of testicular immune privilege. Mol Cell Endocrinol [Internet];335(1):60\u201368. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0303720710001863","DOI":"10.1016\/j.mce.2010.03.022"},{"key":"11367_CR82","doi-asserted-by":"crossref","unstructured":"Ridolfi L, Petrini M, Fiammenghi L, Riccobon A, Ridolfi R (2009) Human embryo immune escape mechanisms rediscovered by the tumor. Immunobiology [Internet];214(1):61\u201376. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0171298508000363","DOI":"10.1016\/j.imbio.2008.03.003"},{"key":"11367_CR83","doi-asserted-by":"crossref","unstructured":"Flint TR, Jones JO, Ferrer M, Colucci F, Janowitz T (2018) A comparative analysis of immune privilege in pregnancy and cancer in the context of checkpoint blockade immunotherapy. Semin Oncol [Internet];45(3):170\u2013175. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0093775418300678","DOI":"10.1053\/j.seminoncol.2018.03.005"},{"key":"11367_CR84","first-page":"171","volume":"6","author":"SS Morelli","year":"2015","unstructured":"Morelli SS, Mandal M, Goldsmith LT, Kashani BN, Ponzio NM (2015) The maternal immune system during pregnancy and its influence on fetal development. Res Rep Biol 6:171\u2013189","journal-title":"Res Rep Biol"},{"issue":"8","key":"11367_CR85","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1084\/jem.20030305","volume":"198","author":"LA Koopman","year":"2003","unstructured":"Koopman LA, Kopcow HD, Rybalov B, Boyson JE, Orange JS, Schatz F et al (2003) Human decidual natural killer cells are a unique NK cell subset with immunomodulatory potential. J Exp Med 198(8):1201\u201312","journal-title":"J Exp Med"},{"key":"11367_CR86","doi-asserted-by":"crossref","unstructured":"Greten FR, Grivennikov SI (2019) Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity [Internet];51(1):27\u201341. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S107476131930295X","DOI":"10.1016\/j.immuni.2019.06.025"},{"issue":"5","key":"11367_CR87","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nri.2017.142","volume":"18","author":"K Taniguchi","year":"2018","unstructured":"Taniguchi K, Karin M (2018) NF-\u03baB, inflammation, immunity and cancer: coming of age. Nat Rev Immunol 18(5):309\u201324. https:\/\/doi.org\/10.1038\/nri.2017.142","journal-title":"Nat Rev Immunol"},{"issue":"6230","key":"11367_CR88","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","volume":"348","author":"JA Joyce","year":"2015","unstructured":"Joyce JA, Fearon DT (2015) T cell exclusion, immune privilege, and the tumor microenvironment. Science (80- ) 348(6230):74\u201380. https:\/\/doi.org\/10.1126\/science.aaa6204","journal-title":"Science (80- )"},{"key":"11367_CR89","doi-asserted-by":"publisher","DOI":"10.4137\/IJTR.S38355","volume":"9","author":"J-P Routy","year":"2016","unstructured":"Routy J-P, Routy B, Graziani GM, Mehraj V (2016) The kynurenine pathway is a double-edged sword in immune-privileged sites and in cancer: implications for immunotherapy. Int J Tryptophan Res 9:IJTR.S38355. https:\/\/doi.org\/10.4137\/IJTR.S38355","journal-title":"Int J Tryptophan Res"},{"issue":"9","key":"11367_CR90","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1158\/1541-7786.MCR-19-0897","volume":"18","author":"K Taguchi","year":"2020","unstructured":"Taguchi K, Onoe T, Yoshida T, Yamashita Y, Tanaka Y, Ohdan H (2020) Tumor endothelial cell\u2013mediated antigen-specific T-cell suppression via the PD-1\/PD-L1 pathway. Mol Cancer Res 18(9):1427\u201340. https:\/\/doi.org\/10.1158\/1541-7786.MCR-19-0897","journal-title":"Mol Cancer Res"},{"key":"11367_CR91","doi-asserted-by":"crossref","unstructured":"Co DO, Hogan LH, Il-Kim S, Sandor M (2004) T cell contributions to the different phases of granuloma formation. Immunol Lett [Internet];92(1):135\u2013142. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0165247803003109","DOI":"10.1016\/j.imlet.2003.11.023"},{"issue":"3","key":"11367_CR92","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S0002-9440(10)63880-1","volume":"162","author":"K Kuwata","year":"2003","unstructured":"Kuwata K, Watanabe H, Jiang S-Y, Yamamoto T, Tomiyama-Miyaji C, Abo T et al (2003) AIM inhibits apoptosis of T cells and NKT cells in Corynebacterium-induced granuloma formation in mice. Am J Pathol 162(3):837\u201347","journal-title":"Am J Pathol"},{"key":"11367_CR93","doi-asserted-by":"publisher","unstructured":"Lundy S, Lukacs N (2013) Chronic schistosome infection leads to modulation of granuloma formation and systemic immune suppression [Internet]. Vol. 4, Frontiers in Immunology. Available from: https:\/\/www.frontiersin.org\/articles\/https:\/\/doi.org\/10.3389\/fimmu.2013.00039","DOI":"10.3389\/fimmu.2013.00039"},{"issue":"7","key":"11367_CR94","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1080\/21645515.2020.1870364","volume":"17","author":"T Kubo","year":"2021","unstructured":"Kubo T, Hirohashi Y, Tsukahara T, Kanaseki T, Murata K, Hasegawa T et al (2021) Epithelioid granulomatous lesions express abundant programmed death ligand-1 (PD-L1): a discussion of adverse events in anti-PD-1 antibody-based cancer immunotherapy. Hum Vaccin Immunother 17(7):1940\u20132","journal-title":"Hum Vaccin Immunother"},{"key":"11367_CR95","doi-asserted-by":"crossref","unstructured":"Wiggins CJ, Chon SY (2020) Anti-CTLA-4 therapy-associated granuloma annulare in chronic myelomonocytic leukemia. In Proceedings (Baylor University. Medical Center) (Vol. 34,\u00a0pp 122\u2013123). United States\u00a0","DOI":"10.1080\/08998280.2020.1818165"},{"issue":"15_suppl","key":"11367_CR96","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.9582","volume":"39","author":"A Noor","year":"2021","unstructured":"Noor A, Yassine I, Lee SJ, Othus M, Moon J, Kirkwood JM et al (2021) Granulomatous and sarcoid-like immune related adverse events (irAEs) in melanoma patients following CTLA4 blockade adjuvant therapy: an analysis of 1670 high-risk patients. J Clin Oncol 39(15_suppl):9582. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.9582","journal-title":"J Clin Oncol"},{"issue":"1","key":"11367_CR97","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/j.1600-065X.2006.00431.x","volume":"213","author":"OI Iweala","year":"2006","unstructured":"Iweala OI, Nagler CR (2006) Immune privilege in the gut: the establishment and maintenance of non-responsiveness to dietary antigens and commensal flora. Immunol Rev 213(1):82\u2013100. https:\/\/doi.org\/10.1111\/j.1600-065X.2006.00431.x","journal-title":"Immunol Rev"},{"key":"11367_CR98","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a018341","author":"OJ Harrison","year":"2013","unstructured":"Harrison OJ, Powrie FM (2013) Regulatory t cells and immune tolerance in the intestine. Cold Spring Harb Perspect Biol. https:\/\/doi.org\/10.1101\/cshperspect.a018341","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"11367_CR99","doi-asserted-by":"publisher","unstructured":"Vitetta L, Vitetta G, Hall S (2018) Immunological Tolerance and Function: Associations Between Intestinal Bacteria, Probiotics, Prebiotics, and Phages [Internet]. Vol. 9, Frontiers in Immunology. Available from: https:\/\/www.frontiersin.org\/articles\/https:\/\/doi.org\/10.3389\/fimmu.2018.02240","DOI":"10.3389\/fimmu.2018.02240"},{"key":"11367_CR100","doi-asserted-by":"publisher","unstructured":"M\u00f6lzer C, Heissigerova J, Wilson HM, Kuffova L, Forrester JV (2021) Immune Privilege: The Microbiome and Uveitis [Internet]. Vol. 11, Frontiers in Immunology. Available from: https:\/\/www.frontiersin.org\/articles\/https:\/\/doi.org\/10.3389\/fimmu.2020.608377","DOI":"10.3389\/fimmu.2020.608377"},{"issue":"12","key":"11367_CR101","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/35103104","volume":"2","author":"DR Green","year":"2001","unstructured":"Green DR, Ferguson TA (2001) The role of Fas ligand in immune privilege. Nat Rev Mol Cell Biol 2(12):917\u201324. https:\/\/doi.org\/10.1038\/35103104","journal-title":"Nat Rev Mol Cell Biol"},{"key":"11367_CR102","doi-asserted-by":"crossref","unstructured":"Collins M, Michot JM, Danlos FX, Mussini C, Soularue E, Mateus C et al (2017) Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies. Ann Oncol [Internet].28(11):2860\u20132865. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0923753419345879","DOI":"10.1093\/annonc\/mdx403"},{"key":"11367_CR103","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S499403","author":"S Zhang","year":"2025","unstructured":"Zhang S, Chen W, Zhou J, Liang Q, Zhang Y, Su M et al (2025) The benefits and safety of monoclonal antibodies: implications for cancer immunotherapy. J Inflamm Res. https:\/\/doi.org\/10.2147\/JIR.S499403","journal-title":"J Inflamm Res"},{"issue":"3","key":"11367_CR104","doi-asserted-by":"publisher","first-page":"227","DOI":"10.14744\/ejmo.2023.38141","volume":"7","author":"L Han","year":"2023","unstructured":"Han L, Yuan Y, Feng Y, Li X (2023) Association of serum Interleukin-6 and Interleukin-8 levels with clinical benefit from immune checkpoint inhibitors in patients with advanced gastric cancer. Eurasian J Med Oncol 7(3):227\u2013231","journal-title":"Eurasian J Med Oncol"},{"issue":"9","key":"11367_CR105","first-page":"1","volume":"85","author":"Y Huang","year":"2024","unstructured":"Huang Y, Yu W (2024) Advances in immune checkpoint therapy in hepatocellular carcinoma. Br J Hosp Med 85(9):1\u201321","journal-title":"Br J Hosp Med"},{"key":"11367_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.113664","volume":"382","author":"J Yang","year":"2025","unstructured":"Yang J, Zhu J, Lu S, Qin H, Zhou W (2025) Transdermal psoriasis treatment inspired by tumor microenvironment-mediated immunomodulation and advanced by exosomal engineering. J Control Release 382:113664","journal-title":"J Control Release"},{"issue":"1","key":"11367_CR107","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/imm.13793","volume":"173","author":"Z Wang","year":"2024","unstructured":"Wang Z, Zhang X, Fang C, Liu X, Liao Q, Wu N et al (2024) Immunotherapy and the ovarian cancer microenvironment: exploring potential strategies for enhanced treatment efficacy. Immunology 173(1):14\u201332","journal-title":"Immunology"},{"issue":"1","key":"11367_CR108","doi-asserted-by":"publisher","first-page":"28","DOI":"10.36922\/arnm.5132","volume":"3","author":"L Lukas","year":"2025","unstructured":"Lukas L, Han HR, Torres ETR, Baugh AG, Bell O, Ye JC et al (2025) Targeting EZH2 to mitigate immune checkpoint resistance in ARID1A-deficient triple-negative breast cancer. Advances in Radiotherapy & Nuclear Medicine 3(1):28\u201345","journal-title":"Advances in Radiotherapy & Nuclear Medicine"},{"key":"11367_CR109","doi-asserted-by":"publisher","first-page":"1647066","DOI":"10.3389\/fimmu.2025.1647066","volume":"16","author":"MA Alsayb","year":"2025","unstructured":"Alsayb MA (2025) Innovations in immunotherapy for autoimmune diseases: recent breakthroughs and future directions. Front Immunol 16:1647066","journal-title":"Front Immunol"},{"issue":"5","key":"11367_CR110","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s10637-024-01472-w","volume":"42","author":"L Peng","year":"2024","unstructured":"Peng L, Wu Z, Sun W, Wang C (2024) Clinical characteristics, treatment, and outcomes of nivolumab induced immune thrombocytopenia. Invest New Drugs 42(5):575\u2013580","journal-title":"Invest New Drugs"},{"issue":"6","key":"11367_CR111","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1080\/08923973.2024.2402338","volume":"46","author":"Y He","year":"2024","unstructured":"He Y, Fan Z, Sun W, Ouyang L, Wang C (2024) Clinical features, treatment, and outcome of nivolumab-induced cholangitis. Immunopharmacol Immunotoxicol 46(6):757\u2013762","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"2","key":"11367_CR112","doi-asserted-by":"publisher","first-page":"116","DOI":"10.20892\/j.issn.2095-3941.2017.0086","volume":"15","author":"L Jia","year":"2018","unstructured":"Jia L, Zhang Q, Zhang R (2018) PD-1\/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy. Cancer Biol Med 15(2):116\u2013123","journal-title":"Cancer Biol Med"},{"key":"11367_CR113","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2147\/OTT.S4833","volume":"3","author":"AA Tarhini","year":"2010","unstructured":"Tarhini AA, Iqbal F (2010) CTLA-4 blockade: therapeutic potential in cancer treatments. Onco Targets Ther 3:15\u201325","journal-title":"Onco Targets Ther"},{"issue":"9","key":"11367_CR114","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1038\/s41591-023-02498-y","volume":"29","author":"A VanderWalde","year":"2023","unstructured":"VanderWalde A, Bellasea SL, Kendra KL, Khushalani NI, Campbell KM, Scumpia PO et al (2023) Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial. Nat Med 29(9):2278\u201385. https:\/\/doi.org\/10.1038\/s41591-023-02498-y","journal-title":"Nat Med"},{"key":"11367_CR115","doi-asserted-by":"publisher","unstructured":"Dirk ATH, LE SJ, AP A, Luis M, Erika CG et al (2022) Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med [Internet];386(1):24\u201334. Available from: https:\/\/doi.org\/10.1056\/NEJMoa2109970","DOI":"10.1056\/NEJMoa2109970"},{"key":"11367_CR116","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf144","author":"ME Gutierrez","year":"2025","unstructured":"Gutierrez ME, Tang S-C, Powderly JD 2nd, Balmanoukian AS, Hoyle PE, Dong Z et al (2025) First-in-human phase I open-label study of the anti-TIM-3 monoclonal antibody INCAGN02390 in patients with select advanced or metastatic solid tumors. Oncologist. https:\/\/doi.org\/10.1093\/oncolo\/oyaf144","journal-title":"Oncologist"},{"issue":"1","key":"11367_CR117","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41416-024-02887-1","volume":"132","author":"B Jayathilaka","year":"2025","unstructured":"Jayathilaka B, Mian F, Franchini F, Au-Yeung G, IJzerman M (2025) Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review. Br J Cancer 132(1):51\u20137. https:\/\/doi.org\/10.1038\/s41416-024-02887-1","journal-title":"Br J Cancer"},{"key":"11367_CR118","doi-asserted-by":"publisher","unstructured":"Jay T, Edit D, Abraham S-CJ, Paul E, Maria G, Alan K et al (2023) A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis. N Engl J Med [Internet];388(20):1853\u20131862. Available from: https:\/\/doi.org\/10.1056\/NEJMoa2209856","DOI":"10.1056\/NEJMoa2209856"},{"key":"11367_CR119","doi-asserted-by":"publisher","unstructured":"Flavio V, Lionel R, Joseph G, Kim R, Steven S, Luis G et al (2025) Belatacept and Long-Term Outcomes in Kidney Transplantation. N Engl J Med [Internet]. ;374(4):333\u201343. Available from: https:\/\/doi.org\/10.1056\/NEJMoa1506027","DOI":"10.1056\/NEJMoa1506027"},{"issue":"10429","key":"11367_CR120","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/S0140-6736(23)02649-1","volume":"403","author":"AP Cope","year":"2024","unstructured":"Cope AP, Jasenecova M, Vasconcelos JC, Filer A, Raza K, Qureshi S et al (2024) Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial. Lancet 403(10429):838\u201349. https:\/\/doi.org\/10.1016\/S0140-6736(23)02649-1","journal-title":"Lancet"},{"issue":"Supplement_1","key":"11367_CR121","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjy222.042","volume":"13","author":"M Angin","year":"2019","unstructured":"Angin M, Brignone C, Triebel F (2019) DOP07 IMP761, a novel anti-LAG-3 agonist antibody for the treatment of auto-immune diseases. J Crohns Colitis 13(Supplement_1):S031\u2013S031. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjy222.042","journal-title":"J Crohns Colitis"},{"issue":"11","key":"11367_CR122","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1002\/ijc.32661","volume":"146","author":"M Nikanjam","year":"2020","unstructured":"Nikanjam M, Arguello D, Gatalica Z, Swensen J, Barkauskas DA, Kurzrock R (2020) Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients. Int J Cancer 146(11):3087\u20133097","journal-title":"Int J Cancer"},{"key":"11367_CR123","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13184659","author":"YA Cho","year":"2021","unstructured":"Cho YA, Lee H, Kim DG, Kim H, Ha SY, Choi Y-L et al (2021) PD-L1 expression is significantly associated with tumor mutation burden and microsatellite instability score. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13184659","journal-title":"Cancers (Basel)"},{"issue":"1","key":"11367_CR124","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1186\/s12885-024-12271-0","volume":"24","author":"Y Guo","year":"2024","unstructured":"Guo Y, Pan Y, Wan J, Gong B, Li Y, Kan X et al (2024) Prognosis stratification of cancer patients treated with immune checkpoint inhibitors through lung immune prognostic index: a meta-analysis and systematic review. BMC Cancer 24(1):523","journal-title":"BMC Cancer"},{"issue":"2","key":"11367_CR125","doi-asserted-by":"publisher","first-page":"103","DOI":"10.5306\/wjco.v12.i2.103","volume":"12","author":"M Peravali","year":"2021","unstructured":"Peravali M, Gomes-Lima C, Tefera E, Baker M, Sherchan M, Farid S et al (2021) Racial disparities in immune-related adverse events of immune checkpoint inhibitors and association with survival based on clinical and biochemical responses. World J Clin Oncol 12(2):103\u201314","journal-title":"World J Clin Oncol"},{"issue":"1","key":"11367_CR126","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2458948","volume":"21","author":"J Le","year":"2025","unstructured":"Le J, Sun Y, Deng G, Dian Y, Xie Y, Zeng F (2025) Immune checkpoint inhibitors in cancer patients with autoimmune disease: safety and efficacy. Hum Vaccin Immunother 21(1):2458948","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"11367_CR127","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1634\/theoncologist.2018-0764","volume":"24","author":"ME Sise","year":"2019","unstructured":"Sise ME, Seethapathy H, Reynolds KL (2019) Diagnosis and management of immune checkpoint inhibitor-associated renal toxicity: illustrative case and review. Oncologist 24(6):735\u2013742","journal-title":"Oncologist"},{"issue":"12","key":"11367_CR128","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100880","volume":"5","author":"L Parlati","year":"2023","unstructured":"Parlati L, Sakka M, Retbi A, Bouam S, Hassani L, Meritet J-F et al (2023) Burden of grade 3 or 4 liver injury associated with immune checkpoint inhibitors. JHEP Rep 5(12):100880","journal-title":"JHEP Rep"},{"issue":"2","key":"11367_CR129","doi-asserted-by":"publisher","first-page":"111","DOI":"10.6004\/jadpro.2024.15.2.4","volume":"15","author":"SM Otto","year":"2024","unstructured":"Otto SM, Martinez AL, Dains JE (2024) Risk factors for immune checkpoint inhibitor-related myocarditis: an integrative review. J Adv Pract Oncol 15(2):111\u2013123","journal-title":"J Adv Pract Oncol"},{"issue":"5","key":"11367_CR130","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.3390\/curroncol28050283","volume":"28","author":"A Paderi","year":"2021","unstructured":"Paderi A, Fancelli S, Caliman E, Pillozzi S, Gambale E, Mela MM et al (2021) Safety of immune checkpoint inhibitors in elderly patients: an observational study. Curr Oncol 28(5):3259\u201367","journal-title":"Curr Oncol"},{"key":"11367_CR131","doi-asserted-by":"crossref","unstructured":"Yamauchi I, Yabe D (2025) Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors. Eur Thyroid J;14(1)","DOI":"10.1530\/ETJ-24-0328"},{"issue":"24","key":"11367_CR132","doi-asserted-by":"publisher","first-page":"9595","DOI":"10.1002\/cam4.3525","volume":"9","author":"F Ge","year":"2020","unstructured":"Ge F, Li C, Xu X, Huo Z, Wang R, Wen Y et al (2020) Cancer risk in heart or lung transplant recipients: a comprehensive analysis of 21 prospective cohorts. Cancer Med 9(24):9595\u2013610","journal-title":"Cancer Med"},{"key":"11367_CR133","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1146002","volume":"13","author":"R Shaw","year":"2023","unstructured":"Shaw R, Haque AR, Luu T, O\u2019Connor TE, Hamidi A, Fitzsimons J et al (2023) Multicenter analysis of immunosuppressive medications on the risk of malignancy following adult solid organ transplantation. Front Oncol 13:1146002","journal-title":"Front Oncol"},{"key":"11367_CR134","doi-asserted-by":"crossref","unstructured":"Henriksen NL, Jensen P\u00d8, Jensen LK (2025) Immune checkpoint blockade in experimental bacterial infections. J Infect [Internet].90(2):106391. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0163445324003268","DOI":"10.1016\/j.jinf.2024.106391"}],"updated-by":[{"DOI":"10.1007\/s11033-026-11444-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000}}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-11367-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-11367-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-11367-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T10:47:39Z","timestamp":1768474059000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-11367-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":134,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11367"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-11367-5","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"assertion":[{"value":"6 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: The second author\u2019s name has been corrected to \u201cZahra Nejad Shahrokh Abadi\u201d","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11033-026-11444-3","URL":"https:\/\/doi.org\/10.1007\/s11033-026-11444-3","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"206"}}